I Taylor

BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis

Scott M. Wilhelm, Christopher Carter, LiYa Tang et al. · Cancer Research · 2004 · 4K citations · Full text

Mutant Braf, Raf/mek/erk Pathway, Medicine +12

Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Ghassan K. Abou‐Alfa, Lawrence H. Schwartz, Sergio Ricci et al. · Journal of Clinical Oncology · 2006 · 1.2K citations · Full text

Sorafenib (BAY 43‐9006, Nexavar®), a Dual‐Action Inhibitor That Targets RAF/MEK/ERK Pathway in Tumor Cells and Tyrosine Kinases VEGFR/PDGFR in Tumor Vasculature

Lila Adnane, Pamela A. Trail, I Taylor et al. · Methods in enzymology on CD-ROM/Methods in enzymology · 2006 · 463 citations

Medicine, Receptor Tyrosine Kinase, Pharmacology +8

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

Yong S. Chang, Jalila Adnane, Pamela A. Trail et al. · Cancer Chemotherapy and Pharmacology · 2006 · 462 citations

Oncology, Medicine, Tumor Growth +10

Facilitated binding of GAL4 and heat shock factor to nucleosomal templates: differential function of DNA-binding domains.

I Taylor, Jerry L. Workman, Thomas Schuetz et al. · Genes & Development · 1991 · 269 citations · Full text

Regulatory Factors, Protein Assembly, Genetics +20